Here's A Pharma Stock Has Given Over 100% Returns Since Listing; Do You Own?

Mankind Pharma has witnessed a staggering 100% surge in its shares within a year of going public at Rs 1,080 per share, reaching a high of Rs 2,255 per share on Friday. The pharmaceutical giant made its market debut in May 2023 through an Offer for Sale (OFS) Initial Public Offering (IPO).

Mankind Pharma, with 97% of its revenue generated from its home market - India, has not only established itself as a pharmaceutical giant but also excelled in the consumer healthcare space. The company's foray into consumer healthcare began in 2007, 15 years after its inception in 1991.

Key to Mankind Pharma's success is its consumer healthcare segment, featuring leading brands in the condoms, emergency contraceptives, and pregnancy test space, such as Manforce, Unwanted 72, and Preganews. These brands have emerged as category leaders, achieving a commendable Compounded Annual Growth Rate (CAGR) of 21% between the financial years 2018 and 2023. Remarkably, the entire consumer healthcare segment has registered a 22% CAGR from 2021 to 2023.

Today, 18 out of the company's top 20 brands dominate their respective markets, with 22 portfolio brands valued at over Rs 100 crore. Mankind Pharma holds the fourth position in the Indian Pharmaceutical market by value.

Looking forward, Mankind Pharma is set to diversify further into the chronic drugs segment, which constituted 34% of total pharmaceutical drug sales in the financial year 2023, up from 28% in 2018. This move aligns with the company's ambition to bolster its revenue streams and solidify its standing in the highly competitive pharmaceutical landscape.

Notably, Mankind Pharma has maintained an impressive Revenue Compound Annual Growth Rate (CAGR) of 19% from the financial year 2021 to 2023, with domestic business experiencing an 18% growth during the same period. The company has outpaced the Indian Pharma Market, achieving three times the domestic average volume growth.

At the recent JPMorgan conference, Mankind Pharma revealed plans to enhance the value of prescriptions in its current strongholds. A substantial 68% of its operations in the financial year 2023 were driven by prescriptions. The company also aims to expand its share in the chronic drugs segment by reinforcing its presence in existing therapies and exploring new territories like CNS, Transplant, Urology, and Oncology.

Mankind Pharma plans to increase penetration in metros and tier-I cities, targeting key demographics. Additionally, the company has its sights set on introducing Drug Master File (DMF) quality medicines at affordable prices for the Indian market.

Innovative digital platforms will continue to play a pivotal role in Mankind Pharma's growth strategy. The company aims to enhance doctor engagement through digital channels and capitalize on the evolving landscape of healthcare services.

The shares of Mankind Pharma were seen trading with cuts of more than 1% as of 11:15 am on the National Stock Exchange (NSE).